INDIAN PHARMACEUTICAL INDUSTRY

` ` ` ` ` ` ` ` ` ` `

HISTORY CHARACTERISTIC FUTURE PROSPECTS POSITIONING DOMESTIC INDIAN PHARMA MARKET IMPORT & EXPORT INDIAN PHARMA MARKET TOP 10 PHARMA COMPANIES TOP 10 BRANDS FAST GROWING COMPANIES TOP 5 THERAPEUTIC SEGMENTS MERGER & AQUISITION

YEAR WISE TURN OVER VALUE IN BILLION US$

21.04 16.42 12.56 10.23

2006

2007

2008

2009

Highly fragmented with more than 20,000 registered units and 375 pharma companies. Associated with severe price competition and government price control. Presently growing at 8-9 % growth per annum

` `

Educated work force & english is frequently used 53 years old democracy and having solid framework & strong financial market. International pharma industry finding great opportunities in INDIA. Committed to free market economy & globalization.

Year 2008-09:turn over is 21.04 billion US$.  As per INDIA PHARMA 2020 turn-over is expected to reach 55 billion US$ in 2020.  Domestic pharma-20 billion US$  Health care pharma- 31.59 billion US$ by 2020.  So,india would really become a LUCRATIVE destination for clinical trials.


INDIAN PHARMACEUTICAL INDUSTRY is the 3rd largest in the world in terms of VOLUME. INDIAN PHARMACEUTICAL INDUSTRY is on the 14th position in terms of VALUE.

20 18 16 14 12 10 8 6 4 2 0 2007 2008 2009 SALES IN BILLION US$ GROWTH IN %

30 25 20 15 10 5 0 2003 2004 2005 2006 2007 2008 2009

SALES IN BILLION US$ 2.57 3.04 3.57 4.45 5.38 6. 5 7.69 GROWTH % 18.61 17.38 24.41 21.06 14.37 24.94

SALES IN BILLION US$ 42.07

GROWTH %

30.14 26.87

15.18 7.02 4 0.57 2003 0.59 2004 0.63 2005 0.9 2006 1.17 2007 1.35 2008 1.71 2009

AS MARCH2007

1. 2. 3. 4. 5. 6. 7. 8. 9. 10.

RANBAXY DR.REDDYS LAB CIPLA SUN PHARMA LUPIN LTD AUROBINDO PHARMA GSK ZYDUS CADILA AVENTIS IPCA LAB

1. 2. 3. 4. 5. 6. 7. 8. 9. 10.

CIPLA RANBAXY DR.REDDYS LAB SUN PHARMA LUPIN LTD AUROBINDO PHARMA PIRAMAL HEALTHCARE CADILA MATRIX WOCKHARDT

CONTENT

NAME OF COMPANY

Chlorpheniramine,codein PFIZER e sulphate VOVERAN PHENSEDYL HUMAN MIXTARD LIV-52 TAXIM ZIFI AUGMENTIN MOX ASTHALIN Diclofenac Chlorpheniramine, codeine sulphate. Insulin Ayurvedic product Cefotaxime Cefixime Amoxicillin,clavunic acid Amoxicillin salbutamol PIRAMAL NOVO NORDISK HIMALAYA ALKEM FDC GSK RANBAXY CIPLA

BRAND NAME

NAME OF COMPNAY PFIZER

COMPOSITION

INDICATION

LIPITOR

ATORVASTATIN

HIGH CHOLESTEROL
ATHEROSCLEROSI S

PLAVIX

SANOFI AVENTIS

CLOPIDROGEL

REMICADE

MERCK & CO

INFIXIMAB

RHEUMATOID ARTHRITIS ASTHMA

ADVAIR

GSK

SALMETEROL FLUTICASONE ETANERCEPT

ENBREL

PFIZER

JUVENILE IDIOPATHIC ARTHRITIS

NAME OF THE COMPANY MANKIND SUN PHARMA ABBOTT ZYDUS ALKEM PFIZER

GROWTH RATE
37 % 26 % 25 % 24 % 23.8 % 23.6%

SEGMENT

2006

2007

2008

2009

ANTI-INFECTIVE

43.7

49.7

56.9

64.3

GASTRO-INTESTINAL

27.1

30.5

34.1

38.9

CARDIO

25.3

28.2

30.3

36.5

PAIN/ANALGESIC

21.4

26.3

29.9

36.1

RESPIRATORY

22.9

25.8

28.4

34.6

MERGER:is defined as voluntary amalgamation of two firms on roughly equal terms into one new legal entity. ACQUISITION:The purchase of one corporation by another,through either the purchase of its shares or the purchase of its assets.

Effected by exchange of the pre-merger shares from the stock of the new firms. To increase market shares,to gain access to promising new technologies,to achieve synergies in their operations. To eliminate competition,reduce tax liabilities But it is risky,because many things may go wrong with even a well laid plan to grow by AQUIRING.

PRE MERGER COMPANY

POST MERGER COMPANY ASTRA ZENECA AVENTIS GSK NOVARTIS PFIZER PFIZER SANOFI AVENTIS

YEAR

ASTRA,ZENECA GROUP RHONE LTD GLAXO WELCOMESMITHKLINE BEECHAM SANDOZ PFIZER-LAMBERT PFIZER-PHARMACIA SANOFI-AVENTIS

1999 2000 2000 1996 2000 2003 2004

AQUIRED COMPANY

AQUIRING COMPANY

YEAR

RANBAXY

DAICHI SANKYO

2008

WYETH

PFIZER

2009

PIRAMAL HEALTHCARE

ABBOTT

2010

PARAS

RECKITT BENCKISER

2011

TEVA PHARMA

SUN PHARMA

2011